Application note: High-throughput fluorescence-based mAbs aggregation analysis workflow2SHARES Share via Pinterest Reddit Buffer Xing WhatsApp FlipboardPosted: 5 January 2021 | Agilent | No comments yet Modern biologics development relies on the screening of 100s – 1000s of monoclonal antibody (mAb) variants to identify lead development candidates with optimal properties such as affinity, specificity, immunogenicity, and glycosylation.Antibody aggregation can be an unintended side-effect of these optimizations as it is influenced by molecular attributes as well as those of the expression host. It is controlled and monitored as a critical quality attribute (1). The ability to rapidly assess the propensity of mAb to aggregate is thus a core requirement of modern pharmaceutical development. To read this supplement in full, please complete the form below: First Name * Last Name * Job Title * Company/Org name * Address * Town/City * Postal Code/Zip * Country * —Please choose an option—AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCook IslandsCosta RicaCote D'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFaeroe IslandsFalkland IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadaloupeGuamGuatemalaGuineaGuinea-BissauGuyanaHaitiHeard and McDonald IslandsVatican CityHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKoreaKosovaKuwaitKyrgyz RepublicLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinian TerritoryPanamaPapua New GuineaParaguayPeruPhilippinesPitcairn IslandPolandPortugalPuerto RicoQatarReunionRomaniaRussiaRwandaSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbia and MontenegroSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSpainSri LankaSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudanSurinameSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States Minor Outlying IslandsUnited States of AmericaUruguayUS Virgin IslandsUzbekistanVanuatuVenezuelaVietnamWallis and Futuna IslandsWestern SaharaYemenZambiaZimbabweTelephone * Email * Would you like to be contacted by an Agilent expert to learn more about Agilent Cary Eclipse? *YesNo [checkbox learn_more use_label_element "Yes, I would like to receive email updates about Agilent products, services and events. For full details of how we will treat your information please view our privacy policy: www.agilent.com/home/privacy-policy"] Yes, I would like to receive email updates about Agilent products, services and events. For full details of how we will treat your information please view our privacy policy: www.agilent.com/home/privacy-policyBy clicking submit you confirm that you accept our terms and conditions and privacy policy.Related content from this organisationApplication note: High-throughput fluorescence-based mAbs aggregation analysis workflowApplication Notes & Whitepapers 2020Application Notes & Whitepapers 2020IssueIssue 6 2020Related topicsAntibodies, BiologicsRelated organisationsAgilent, Agilent Technologies
newsTariffs could threaten medicine innovation, industry bodies warnBy Catherine Eckford (European Pharmaceutical Review)
newsAlzheimer’s drug requires strengthened pharmacovigilance approachBy Catherine Eckford (European Pharmaceutical Review)
